-+ 0.00%
-+ 0.00%
-+ 0.00%

ALLOGENE THERAPEUTICS INC - INTERIM FUTILITY ANALYSIS OF MRD CLEARANCE FROM PHASE 2 ALPHA3 TRIAL PLANNED FOR EARLY Q2 2026

Reuters·01/08/2026 13:31:49

Please log in to view news